EGFR and neoplasm: At 50 mg/m2 and at all lower doses, anti-EGFR ILs-dox were well tolerated; grade 1 skin toxicity occurred in two patients, and only 22 serious adverse events were observed in 17 patients, mostly due to tumor progression.21